<u>Kymera Therapeutics Policy for Expanded Access to Investigational Drugs</u>

Kymera is committed to developing potentially transformative medicines for patients with serious diseases who may benefit from new treatment options. The following is Kymera's current policy for evaluating and responding to requests for individual patient access to investigational drugs that are intended to treat serious diseases.

Our product pipeline consists of investigational drugs that are currently being tested in clinical trials and have not yet been approved by the US Food and Drug Administration (FDA). This means that the FDA has not yet approved these investigational drugs nor found them to be safe and effective for any use. Kymera's investigational drugs are currently at a stage in development where we are focused on enrolling patients in our clinical trials and continuing to learn more about our investigational drugs' safety and efficacy. We encourage patients to speak with their physicians about their eligibility for enrollment in any of Kymera's clinical trials whenever possible, because our clinical trials are designed, conducted, and monitored with the intent to advance the development of our investigational drugs in order to make them more broadly available to patients in the future. Additional information about Kymera's ongoing clinical trials is available at https://clinicaltrials.gov using the search term, "Kymera."

At this time, Kymera is not able to make expanded access available to its investigational drugs. Kymera may revise this expanded access policy at any time in the future, and this posting will be updated should there be any policy change.

For more information regarding our investigational drugs, or questions about participation in one of our clinical trials, please submit a request to clinicaltrials@kymeratx.com. Kymera will acknowledge receipt of any expanded access questions within 10 business days of receipt.

For additional information on expanded access to investigational drugs, visit the FDA's website by clicking here.